{"schema_version":"secwatch.filing_event.v1","accession":"0001824293-24-000129","form_type":"8-K","ticker":"GRI","cik":"0001824293","company_name":"GRI Bio, Inc.","filed_at":"2024-09-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.724844+00:00","generated_at":"2026-05-31T06:06:31.952593+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.15,"confidence":"high","headline":"GRI Bio shareholders reject equity plan increase by 600K shares; director David Baker elected","bullets":["David Baker elected Class I director with 61,134 for vs 40,091 against (155 abstain).","Ratification of Sadler, Gibb & Associates as auditor passed: 285,641 for, 25,988 against.","Proposal to issue shares underlying warrants (Nasdaq Rule 5635(d)) passed: 51,165 for, 47,971 against.","Amendment to 2018 Equity Incentive Plan to add 600,000 shares failed: 31,556 for, 68,911 against.","Quorum of 311,668 shares (42% of eligible) present at reconvened annual meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001824293-24-000129","json":"https://secwatch.observer/filing/0001824293-24-000129.json","markdown":"https://secwatch.observer/filing/0001824293-24-000129.md","text":"https://secwatch.observer/filing/0001824293-24-000129.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1824293/000182429324000129/0001824293-24-000129-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1824293/000182429324000129/val-20240906.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T06:06:31.952593+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}